-transparent.png){kind=logo}
The present investigation was carried out in 16 healthy subjects in order to study whether calcium antagonism would affect the hypoglycemic response to insulin, and/or whether it would affect the insulin and glucose responses to glucagon. For this purpose verapamil, a potent calcium-blocking agent, was used. Verapamil infused alone did not affect the basal insulin or glucose concentrations. However, such infusion reduced the hypoglycemic response to insulin. Furthermore, the glucose response to glucagon was augmented by simultaneous infusion of verapamil, whereas the insulin response to glucagon was unaffected. When healthy volunteers were simultaneously infused with both calcium and verapamil the glucose response to glucagon was no longer augmented. The insulin response to glucagon also remained unaffected. These findings indicate that intravenous verapamil has hyperglycemic effects, unrelated to insulin, under certain conditions. They also imply that exogenous hypercalcemia counteracts the augmentative effect of verapamil on the glucose response to glucagon.
S Röjdmark, and
D E Andersson, and
R Hed, and
L Sundblad
January 1982,
Panminerva medica,
S Röjdmark, and
D E Andersson, and
R Hed, and
L Sundblad
June 1970,
The American journal of clinical nutrition,
S Röjdmark, and
D E Andersson, and
R Hed, and
L Sundblad
January 1988,
Israel journal of medical sciences,
S Röjdmark, and
D E Andersson, and
R Hed, and
L Sundblad
January 1983,
Panminerva medica,
S Röjdmark, and
D E Andersson, and
R Hed, and
L Sundblad
March 1976,
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
S Röjdmark, and
D E Andersson, and
R Hed, and
L Sundblad
February 1970,
Diabetologia,
S Röjdmark, and
D E Andersson, and
R Hed, and
L Sundblad
July 1973,
The Journal of laboratory and clinical medicine,
S Röjdmark, and
D E Andersson, and
R Hed, and
L Sundblad
September 1991,
Diabetologia,
S Röjdmark, and
D E Andersson, and
R Hed, and
L Sundblad
January 1978,
Chronobiologia,
S Röjdmark, and
D E Andersson, and
R Hed, and
L Sundblad
June 1988,
Lancet (London, England),
